홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
IMCR
#1803
Immunocore Holdings plc American Depositary Shares
32.300
0
+2.28%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
+2.28%
월간 변동
-8.00%
6달 변화
-3.52%
년간 변동율
-3.52%
이전 종가
31.580
0
Open
32.300
0
Bid
Ask
Low
32.300
0
High
32.300
0
양
17
마켓
주식
헬스케어
IMCR
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
Q4, 25
Total assets
1.08 B
1.01 B
1.03 B
1.08 B
1.1 B
1.07 B
Total liabilities
706.81 M
648.79 M
649.53 M
693.91 M
705.94 M
686.24 M
Total equity
377.83 M
360.72 M
378.48 M
388.48 M
396.56 M
381.03 M
Total liabilities & shareholders' equities
1.08 B
1.01 B
1.03 B
1.08 B
1.1 B
1.07 B
Total debt
—
—
—
—
—
—
Net debt
—
—
—
—
—
—
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
뉴스
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
이뮤노코어 홀딩스 Q4 실적, 수익 에상치보다 저조
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
이뮤노코어, 흑색종 파이프라인 진전 속 실적 발표 예정
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down
Immunocore (IMCR) Upgraded to Strong Buy: Here's Why